Ms. Oluwatobi Clement serves as Chief Liaison Officer as well as Secretary to the Board of Directors of HopeScan Initiative. Based in the Washington, DC/Baltimore area, Oluwatobi is a seasoned clinical research professional with extensive experience spanning Oncology, Neuroscience, and early-phase drug development.

Her career includes leadership roles supervising complex leukemia trial portfolios at Memorial Sloan Kettering Cancer Center, contributing to the clinical development of immuno-oncology therapies, including FDA-approved indications in urothelial carcinoma at Merck, and coordinating Phase I to III studies at NYU Langone Medical Center and Dana-Farber/Harvard Cancer Center.

With expertise in clinical operations, medical monitoring, pharmacovigilance, and data review, she brings a strong commitment to advancing early cancer detection, translational science, and equitable healthcare innovation.

She holds an MS in Translational Pharmacology from The Ohio State University, and a BA in Neuroscience from Pomona College, CA. She is currently a Clinical Scientist in General & Specialty Medicine, Neurosciences at Merck Pharmaceutical.